US Patent Issued to Shanghai Acemab on July 21 for "Anti-BCMA antibody, pharmaceutical composition of same, and applications thereof" (Chinese Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,723, issued on July 21, was assigned to Shanghai Acemab Corporation Ltd. (Shanghai).

"Anti-BCMA antibody, pharmaceutical composition of same, and applications thereof" was invented by Jianliang Li (Xiangtan, China), Seeheng Wong (Xiangtan, China), Junxia Zhang (Xiangtan, China), Meng Tian (Xiangtan, China) and Wei Cai (Xiangtan, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided in the present invention are an anti-BCMA antibody, a pharmaceutical composition of same, and applications thereof. The anti-BCMA antibody of the present invention or an antigen binding fragment of same and the pharmaceutical composition thereof are applicable in ...